Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Melanoma 21Breast Neoplasms 19Prostatic Neoplasms 12Neuroblastoma 11Multiple Myeloma 11Leukemia 11Leukemia, Myeloid, Acute 10Lymphoma 9Lymphoma, Non-Hodgkin 8Leukemia, Lymphocytic, Chronic, B-Cell 8Breast Neoplasms, Male 8Glioblastoma 7Ovarian Neoplasms 6Myelodysplastic Syndromes 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Fallopian Tube Neoplasms 5Colorectal Neoplasms 5Neoplasms 4Lymphoma, Follicular 4Leukemia, Myeloid, Chronic-Phase 4Hodgkin Disease 4Glioma 4Carcinoma, Ovarian Epithelial 4Uveal Melanoma 3Rhabdomyosarcoma 3Pancreatic Neoplasms 3Medulloblastoma 3Lung Neoplasms 3

Interventions

Carboplatin 49Etoposide 46Cisplatin 42Topotecan 39Irinotecan 21Paclitaxel 20Nivolumab 15pembrolizumab 13Gemcitabine 13atezolizumab 11Ipilimumab 11durvalumab 9Radiotherapy 9Doxorubicin 7Bevacizumab 7rovalpituzumab tesirine 6etoposide phosphate 6amrubicin 6Psychiatric Rehabilitation 6PM 01183 6Docetaxel 6Counseling 6trilaciclib 5Temozolomide 5Sunitinib 5Platinum 5Imatinib Mesylate 5Cyclophosphamide 5Bortezomib 5130-nm albumin-bound paclitaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Small Cell Lung Carcinoma × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡